Article info

Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression

Authors

  • Sofia Pitsigavdaki Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece PubMed articlesGoogle scholar articles
  • Myrto Nikoloudaki Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece PubMed articlesGoogle scholar articles
  • Panagiotis Garantziotis Laboratory of Autoimmunity and Inflammation, Centre of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital of Erlangen, Erlangen, Germany PubMed articlesGoogle scholar articles
  • Ettore Silvagni Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy PubMed articlesGoogle scholar articles
  • Argyro Repa Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece PubMed articlesGoogle scholar articles
  • Antonio Marangoni Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy PubMed articlesGoogle scholar articles
  • Irini Flouri Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece PubMed articlesGoogle scholar articles
  • Nestor Avgoustidis Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece PubMed articlesGoogle scholar articles
  • Konstantinos Parperis Division of Rheumatology, Department of Medicine, University of Cyprus Medical School, Nicosia, Cyprus PubMed articlesGoogle scholar articles
  • Antonis Fanouriakis Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece PubMed articlesGoogle scholar articles
  • Marcello Govoni Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy PubMed articlesGoogle scholar articles
  • Prodromos Sidiropoulos Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece Division of Immunity, Institute of Molecular Biology and Biotechnology-Foundation for Research and Technology – Hellas (FORTH), Heraklion, Greece PubMed articlesGoogle scholar articles
  • Dimitrios T Boumpas Laboratory of Autoimmunity and Inflammation, Centre of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece PubMed articlesGoogle scholar articles
  • Alessandra Bortoluzzi Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy PubMed articlesGoogle scholar articles
  • George Bertsias Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece Division of Immunity, Institute of Molecular Biology and Biotechnology-Foundation for Research and Technology – Hellas (FORTH), Heraklion, Greece PubMed articlesGoogle scholar articles
  1. Correspondence to Dr George Bertsias, Rheumatology, University of Crete School of Medicine, Iraklio 71003, Greece; gbertsias{at}uoc.gr
View Full Text

Citation

Pitsigavdaki S, Nikoloudaki M, Garantziotis P, et al
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression

Publication history

  • Received August 25, 2023
  • Accepted December 29, 2023
  • First published January 17, 2024.
Online issue publication 
March 12, 2024

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.